To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Completed

Conditions studied: Extensive-stage Small-cell Lung Cancer

In brief

To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.

Key facts

Study ID: NCT04894591
Run by: Jazz Pharmaceuticals
People needed: 272
Starts: 2021-06-28
Expected to finish: 2025-06-04
Last updated by the study team: 2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information.
Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study.
Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
Patients initiating Zepzelca treatment in second-line.
Patients who are sensitive to platinum-based chemotherapy with CTFI≥180 days. The CTFI is defined as the length of time from last platinum dose to time of relapse or disease progression.
Eastern Cooperative Oncology Group performance status (ECOG) ≤1

You may not qualify if…

Patients who discontinued a prior Zepzelca treatment due to adverse events.
Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule.
Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.
Known CNS involvement prior to Zepzelca treatment.
Patients who were treated with Zepzelca in later lines rather than in second-line treatment

Where it is running

Clearview Cancer Institute — Huntsville, Alabama, United States
Eastern Connecticut Hematology and Oncology — Norwich, Connecticut, United States
ASCLEPES Research Centers — Brooksville, Florida, United States
Woodlands Medical Specialists - Woodlands Center For Specialized Medicine — Pensacola, Florida, United States
Mid-Illinois Hematology & Oncology Associates — Normal, Illinois, United States
Goshen Health Center for Cancer Care — Goshen, Indiana, United States
Siouxland Regional Cancer Center dba June E. Nylen Cancer Center — Sioux City, Iowa, United States
Stormont-Vail Cancer Center-Stormont-Vail Healthcare - Cotton-O'Neil Cancer Center — Topeka, Kansas, United States
Cancer Center of Kansas — Wichita, Kansas, United States
Baptist Health Lexington — Lexington, Kentucky, United States
Pikeville Medical Center - Leonard Lawson Cancer Center — Pikeville, Kentucky, United States
West Jefferson Cancer Center — Marrero, Louisiana, United States
MMCORC - HealthPartners Institute — Saint Louis Park, Minnesota, United States
Singing River Health System — Pascagoula, Mississippi, United States
Central Care Cancer Center — Bolivar, Missouri, United States
Benefis Medical Group — Great Falls, Montana, United States
Regional Cancer Care Associates LLC (RCCA) — Hackensack, New Jersey, United States
Center for Clinical Research-Rochester General Hospital — Rochester, New York, United States
Montefiore Medical Center (MMC) - Montefiore Medical Park (MMP) — The Bronx, New York, United States
University of North Carolina NASH Cancer Center — Rocky Mount, North Carolina, United States
Trinity Cancercare Center — Minot, North Dakota, United States
Gabrail Cancer Center Research — Canton, Ohio, United States
Tri-County Hematology & Oncology Associates, Inc — Massillon, Ohio, United States
Lankenau Institute for Medical Research — Wynnewood, Pennsylvania, United States
Charleston Hematology Oncology Associates, PA — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.